# US 2022/0031640 A1 · Formulations for epidural repair

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031640 A1
- Document ID: US20220031640A1
- Status: Published application
- Kind: A1
- Application number: 17/493,801
- Filed: 2021-10-04
- Published: 2022-02-03
- Earliest claimed: 2013-07-25
- Assignees: Claridei Laboratories, Inc.
- Applicants: Claridei Laboratories, Inc.
- Inventors: Cheryl Lee Eberting
- Web page: https://patentgrep.com/patent/US20220031640A1

## CPC

- A61K 31/164: of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A61K 8/361: {Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof}
- A61K 8/365: Hydroxycarboxylic acids; Ketocarboxylic acids
- A61K 8/37: Esters of carboxylic acids
- A61K 8/41: Amines
- A61K 8/42: Amides
- A61K 8/44: Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K 8/4926: {having six membered rings}
- A61K 8/55: Phosphorus compounds
- A61K 8/63: Steroids; Derivatives thereof
- A61K 8/68: Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/133: having hydroxy groups, e.g. sphingosine
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 31/23: of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/007: {Preparations for dry skin}
- A61K 2800/48: Thickener, Thickening system
- A61K 2800/5922: At least two compounds being classified in the same subclass of A61K8/18
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present disclosure is directed to dermatological formulations and their use for treating a variety of dermatological diseases and disorders, and for repairing and restoring a disrupted epidermal barrier, inhibiting inflammation, restoring a proper environment for maintaining a balanced symbiotic microbiome, and inhibiting the growth of pathogenic microorganisms in the epidermis—the outer layer of mammalian skin.

## Claims

### Claim 1

A composition comprising therapeutically effective amounts of at least one of each of the following:
18β-glycyrrhetinic acid;
a glucocorticoid,
a ceramide; and
polyhydroxy acid to maintain a pH of 4.6-5.6.

### Claim 2 (depends on 1)

The composition of claim 1, further comprising a therapeutically effective amount of nicotinamide.

### Claim 3 (depends on 1)

The composition of claim 1, further comprising a phytosphingosine.

### Claim 4 (depends on 1)

The composition of claim 1, further comprising isostearyl isostearate;

### Claim 5 (depends on 1)

The composition of claim 1, wherein the glucocorticoid comprises hydrocortisone.

### Claim 6 (depends on 1)

The composition of claim 1, further comprising a calcium chelator

### Claim 7 (depends on 6)

The composition of claim 6, wherein the calcium chelator comprises at least one of ethylenediaminetetraacetic acid (EDTA) and phytic acid.

### Claim 8 (depends on 1)

The composition of claim 1, further comprising a therapeutically effective amount of fluocinonide.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the glucocorticoid comprises at least one of: triamcinolone, clobetasol, betamethasone, and fluticasone.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the ceramide is chosen from at least one of Cer 1 [EOS], Cer 2 [NS], Cer 3 [NP], Cer 4 [EON], Cer 5 [AS], Cer 6 [AP], Cer 7 [AH], Cer 8 [NH], and Cer 9 [EOP].

### Claim 11 (depends on 1)

The composition of claim 1, further comprising a cholesterol/lanosterol ester.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the cholesterol and/or lanosterol ester is chosen from at least one of cholesterol oleate, cholesterol laurate, cholesterol myristate, cholesterol palmitate, cholesterol stearate, cholesterol arachidate, cholesterol behenate, cholesterol lignocerate, cholesterol cerotate, cholesterol montanate, cholesterol melissate, lanosterol oleate, lanosterol laurate, lanosterol myristate, lanosterol palm itate, lanosterol stearate, lanosterol arachidate, lanosterol behenate, lanosterol lignocerate, lanosterol cerotate, lanosterol montanate, and lanosterol melissate.

### Claim 13 (depends on 1)

The composition of claim 1, further comprising a very long chain fatty acid (VLCFA).

### Claim 14 (depends on 13)

The composition of claim 13, wherein the VLCFA is chosen from at least one of lignoceric acid, cerotic acid, montanic acid, and melissic acid.

### Claim 15 (depends on 1)

The composition of claim 1, comprising a mixture of C10-C30 cholesterol/lanosterol esters.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the polyhydroxy acid is gluconolactone.

### Claim 17

A composition comprising therapeutically effective amounts of the following concentrations of ingredients, in percent weight per weight (w/w):
a ceramide, 0.0001-10% (w/w);
at least one of 18β-glycyrrhetinic acid, glycyrrhizic acid, carbenoxolone, chenodeoxycholic acid, or PF-877423, 0.0001-5% (w/w);
at least one of hydrocortisone, triamcinolone, clobetasol, betamethasone, fluticasone, fluocinonide, 0.001-10.0% (w/w); and
polyhydroxy acid to maintain a pH of 4.6-5.6, X-Y % (w/w).

### Claim 18 (depends on 17)

The composition of claim 17, further comprising therapeutically effective amounts of the following concentrations of ingredients, in percent weight per weight (w/w):
a cholesterol and/or lanosterol ester, 0.0001-10% (w/w);
ethylenediaminetetraacetic acid (EDTA) or phytic acid, 0.01-2.0% (w/w);
nicotinamide, 0.01-10.0% (w/w); and
gluconolactone, 0.01-8.0% (w/w).

### Claim 19 (depends on 17)

The composition of claim 17, further comprising therapeutically effective amounts of the following concentrations of ingredients, in percent weight per weight (w/w):
a very long chain fatty acid VLCFA, 0.01-10% (w/w);
phytosphingosine, 0.0001-10% (w/w); and
isostearyl isostearate, 0.01-10% (w/w);

### Claim 20

A composition comprising therapeutically effective amounts of at least one of each of the following:
a ceramide;
polyhydroxy acid in an amount to maintain a pH of 4.6-5.6;
nicotinamide;
18β-glycyrrhetinic acid;
hydrocortisone; and
gluconolactone.

### Claim 21 (depends on 20)

The composition of claim 20, further comprising therapeutically effective amounts of:
a cholesterol and/or lanosterol ester; and
a very long chain fatty acid VLCFA.
